|
Live online
Classroom
|
2027 |
2028 |
| Apr |
May |
Jun |
Jul |
Aug |
Sep |
Oct |
Nov |
Dec |
Jan |
Feb |
Mar |
|
A Practical Guide to Producing and Maintaining the PSMF & Annexes
|
Vigilance |
|
|
|
|
|
15 |
|
|
|
|
|
|
|
A Practical Guide to Writing Risk Management Plans (RMPs)
|
Vigilance |
|
|
|
|
|
|
18 |
|
|
|
|
|
|
A Practical Introduction to Good Clinical Practice (GCP)
New for 2027
|
GxP |
14 |
|
|
|
|
|
5 |
|
|
|
|
|
|
AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects
|
Artificial Intelligence (AI) in Life Sciences |
|
10 |
|
|
|
|
|
12 |
|
|
|
|
|
AI in Pharmacovigilance
|
Artificial Intelligence (AI) in Life Sciences |
|
17 |
|
|
|
|
|
17 |
|
|
|
|
|
APIs in Focus: Understanding ICH, GMP and Supply Chain Excellence
|
GxP |
28-29 |
|
|
|
|
|
20-21 |
|
|
|
|
|
|
Additional Risk Minimization Measures (aRMMs) and Their Effectiveness
|
Vigilance |
|
|
15 |
|
|
|
|
|
14 |
|
|
|
|
Advanced GMP & GDP Auditor Masterclass
New for 2027
|
GxP |
12-14 |
|
|
|
|
|
12-14 |
|
|
|
|
|
|
Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider
|
Vigilance |
|
|
|
|
|
20-24 |
|
|
|
|
|
|
|
An Essential Overview of Medical Information
|
Regulatory Affairs |
|
|
21 |
|
|
|
|
|
2 |
|
|
|
|
An Introduction to Human Factors for Pharmaceutical and Medical Device Professionals
|
Medical Devices |
|
7 |
|
|
|
|
|
18 |
|
|
|
|
|
An Overview of EU and UK Regulatory Affairs
|
Regulatory Affairs |
|
|
|
|
|
20-21 |
|
|
|
|
|
|
|
An Overview of Ethical Standards in Clinical Research Publication
New for 2026
|
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
|
Antimicrobial Resistance (AMR) and 'One Health': Current Challenges, Regulatory Frontiers and Future Solutions
New for 2026
|
Regulatory Affairs |
|
|
9 |
|
|
|
|
|
8 |
|
|
|
|
Behavioural Risk Management in Clinical Trials
New for 2027
|
Clinical Research |
15 |
|
|
|
|
|
19 |
|
|
|
|
|
|
Best Practices for Supplier Qualification in Life Science
|
Medical Devices |
|
26-27 |
|
|
|
|
|
11-12 |
|
|
|
|
|
Biosimilars
|
Biopharma |
|
|
|
|
|
20-21 |
|
|
|
|
|
|
|
Biotechnology for the Non-Biotechnologist
|
Biopharma |
|
|
9-11 |
|
|
|
|
29-3 |
|
|
|
|
|
CAPA (Corrective and Preventative Action)
|
Regulatory Affairs |
|
|
14 |
|
|
|
|
|
3 |
|
|
|
|
Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products
|
GxP |
22-23 |
|
|
|
|
|
18-19 |
|
|
|
|
|
|
Cleaning Validation - Best Practice in Pharmaceuticals
|
GxP |
|
|
22-23 |
|
|
|
|
23-24 |
|
|
|
|
|
Clinical & Post-Marketing Safety
|
Vigilance |
|
10-11 |
|
|
|
|
|
15-16 |
|
|
|
|
|
Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Applications
|
Regulatory Affairs |
|
|
|
|
|
29-30 |
|
|
|
|
|
|
|
Clinical Quality Management Systems (CQMS): A Practical Guide to Inspection Readiness
|
Clinical Research |
|
|
|
|
|
16-17 |
|
|
|
|
|
|
|
Clinical Research Project Management
|
Leadership & Management for Life Sciences |
28-30 |
|
|
|
|
|
20-22 |
|
|
|
|
|
|
Clinical Trial Agreements: Key Legal, Regulatory and IP Considerations for the EU and UK Markets
New for 2026
|
Commercial Contracts |
|
12 |
|
|
|
|
|
23 |
|
|
|
|
|
Clinical Trial Monitoring
|
Clinical Research |
|
|
17-18 |
|
|
|
|
|
9-10 |
|
|
|
|
Clinical Trial Regulatory Requirements
|
Clinical Research |
|
|
|
|
|
23-24 |
|
|
|
|
|
|
|
Clinical Trials in the MENA Region
New for 2027
|
Clinical Research |
|
26 |
|
|
|
|
|
10 |
|
|
|
|
|
Competition Law for the Pharmaceutical Industry
|
Commercial Contracts |
|
|
|
|
|
|
8 |
|
|
|
|
|
|
Cosmetovigilance
|
Cosmetics |
|
|
17-18 |
|
|
|
|
|
9-10 |
|
|
|
|
Data Integrity and Document Management
|
Medical Devices |
|
|
21 |
|
|
|
|
|
13 |
|
|
|
|
Data-Driven Process Control: Statistical Process Control (SPC) Tools for Quality, Stability, and Performance
New for 2027
|
GxP |
|
|
|
|
|
27-28 |
|
|
|
|
|
|
|
Dealing With Scientific Journal Reviewers: From Comments to Resubmission
New for 2026
|
Medical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
Development of Combination Products: Critical Interactions
|
GxP |
|
|
|
|
|
15-16 |
|
|
|
|
|
|
|
Drafting Commercial Contracts for the Pharmaceutical Industry
|
Commercial Contracts |
|
19-20 |
|
|
|
|
|
10-11 |
|
|
|
|
|
EU Pharmaceutical Regulations and Strategy
|
Regulatory Affairs |
|
|
|
|
|
|
4-5 |
|
|
|
|
|
|
EU Proposed Pharmaceutical Legislation Changes
|
Regulatory Affairs |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
Effective Technical Writing & Editing
|
Medical Writing |
|
14 |
|
|
|
|
|
17 |
|
|
|
|
|
Effective Technology Transfer
|
GxP |
|
|
7-8 |
|
|
|
|
|
7-8 |
|
|
|
|
GMP Advanced Masterclass for Pharmaceutical and Biotechnology Industries
New for 2026
|
GxP |
|
|
7-9 |
|
|
|
|
|
8-10 |
|
|
|
|
GMP Principles in Vaccine Manufacturing
|
GxP |
|
|
15-16 |
|
|
|
|
|
13-14 |
|
|
|
|
Good Distribution Practices of Pharmaceuticals and APIs
|
GxP |
|
20-21 |
|
|
|
|
|
15-16 |
|
|
|
|
|
Good Writing Practice for Clinical Research: Ethics, Standards & Compliance
New for 2026
|
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
|
How the Pharmaceutical and Biotech Industries Work: From Molecule to Market
|
Regulatory Affairs |
|
|
|
|
|
27 |
|
|
|
|
|
|
|
ICH Q12: Advanced Pharmaceutical Product Lifecycle Management in Practice
New for 2027
|
GxP |
|
|
|
7-8 |
|
|
|
|
|
|
|
|
|
ICH Q9(R1) Quality Risk Management (QRM)
|
GxP |
|
|
24 |
|
|
|
|
|
3 |
|
|
|
|
Integrating AI into the GMP Environment
New for 2027
|
Artificial Intelligence (AI) in Life Sciences |
|
7 |
|
|
|
|
|
5 |
|
|
|
|
|
Literature Searching in Drug Safety
|
Vigilance |
|
13-14 |
|
|
|
|
|
9-10 |
|
|
|
|
|
Managing Service Providers including CRO and CMOs oversight to comply with ICH GCP R3
|
Animal Health |
12-13 |
|
|
|
|
|
14-15 |
|
|
|
|
|
|
Mastering CTD Submissions in the MENA Region
|
Regulatory Affairs |
|
25 |
|
|
|
|
|
25 |
|
|
|
|
|
Mastering Computer System Validation
|
GxP |
|
|
16-17 |
|
|
|
|
|
9-10 |
|
|
|
|
Mastering Grant Writing: Essential Skills for Crafting Winning Proposals
New for 2026
|
Medical Writing |
|
|
|
|
|
|
|
|
|
|
|
|
|
Measuring Performance in Clinical Research Management
|
Clinical Research |
|
17 |
|
|
|
|
|
19 |
|
|
|
|
|
Medical Writing with AI
New for 2026
|
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
|
|
|
|
|
|
|
|
|
Microbiomics in Clinical Trials
New for 2027
|
Clinical Research |
|
|
|
|
|
17 |
|
|
|
|
|
|
|
Molecular Biology from Fundamentals to the Latest Applications
|
Biopharma |
19-20 |
|
|
|
|
|
7-8 |
|
|
|
|
|
|
Navigating EU Product Classification: Foods, Supplements & Herbal Medicines Masterclass
Updated for 2026
|
Regulatory Affairs |
|
|
10 |
|
|
|
|
|
3 |
|
|
|
|
New EU GMP Annex 1: Compliant Sterile Medicinal Products
|
GxP |
28-30 |
|
|
|
|
|
4-6 |
|
|
|
|
|
|
Orphan Drug Regulatory Masterclass: EU & US Insights
|
Regulatory Affairs |
|
|
|
|
|
28 |
|
|
|
|
|
|
|
Pharma Facility Project Management: Delivering GMP‑Compliant Sites On Time and Within Budget
New for 2027
|
GxP |
|
|
|
|
|
15-16 |
|
|
|
|
|
|
|
Pharmaceutical Development of ATMPs
|
GxP |
|
|
|
|
|
27-28 |
|
|
|
|
|
|
|
Pharmaceutical Packaging Essentials: From Regulatory Compliance to Market Success
|
GxP |
|
|
|
|
|
21-23 |
|
|
|
|
|
|
|
Pharmaceutical Regulatory Affairs in Asia
|
Regulatory Affairs |
|
|
|
|
|
|
19-21 |
|
|
|
|
|
|
Pharmaceutical Regulatory Affairs in China
|
Regulatory Affairs |
|
19-20 |
|
|
|
|
|
24-25 |
|
|
|
|
|
Pharmaceutical Regulatory Affairs in Russia, Eurasian Union and the CIS
|
Regulatory Affairs |
|
|
|
|
|
29-30 |
|
|
|
|
|
|
|
Pharmaceutical Regulatory Affairs in the Middle East
|
Regulatory Affairs |
12-13 |
|
|
|
|
|
19-20 |
|
|
|
|
|
|
Pharmaceutical Regulatory Affairs in the Middle East and North Africa
|
Regulatory Affairs |
|
|
7-9 |
|
|
|
|
|
|
|
|
|
|
Pharmacovigilance Aspects of Licensing Agreements
|
Vigilance |
|
|
30 |
|
|
|
|
|
8 |
|
|
|
|
Pharmacovigilance QMS & Inspection Preparation
|
Vigilance |
26-27 |
|
|
|
|
|
7-8 |
|
|
|
|
|
|
Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection
|
Vigilance |
29 |
|
|
|
|
|
4 |
|
|
|
|
|
|
Practical Risk Management in Clinical Research and Trials
|
Clinical Research |
23 |
|
|
|
|
|
5 |
|
|
|
|
|
|
Preparing for GCP Inspections: Key Expectations under ICH GCP E6(R3), EU CTR and Current Regulatory Thinking
|
Clinical Research |
|
25 |
|
|
|
|
|
19 |
|
|
|
|
|
Process Validation with Qualification
|
GxP |
|
|
14-15 |
|
|
|
|
|
1-2 |
|
|
|
|
Protein Engineering for Pharmaceutical Biotechnology
New for 2027
|
Biopharma |
|
|
|
|
|
21-22 |
|
|
|
|
|
|
|
Signal Detection and Regulatory Expectations
|
Vigilance |
|
|
|
|
|
29-30 |
|
|
|
|
|
|
|
Smart Packaging and Electronic Patient Information
|
Medical Devices |
|
20 |
|
|
|
|
|
2 |
|
|
|
|
|
Stability Testing of Pharmaceuticals and Biopharmaceuticals
|
GxP |
|
19-21 |
|
|
|
|
|
8-10 |
|
|
|
|
|
Successful Medical Writing – from Protocol to CTD
|
Medical Writing |
|
|
|
|
|
21-22 |
|
|
|
|
|
|
|
The 2024 EU AI Act
New for 2026
|
Artificial Intelligence (AI) in Life Sciences |
|
|
22 |
|
|
|
|
|
2 |
|
|
|
|
The Common Technical Document
|
GxP |
13-14 |
|
|
|
|
|
20-21 |
|
|
|
|
|
|
The FDA Drug Approval Process
|
Regulatory Affairs |
|
|
|
|
|
23-24 |
|
|
|
|
|
|
|
The Principles & Applications of CRISPR
New for 2027
|
Biopharma |
|
|
|
6 |
|
|
|
|
|
|
|
|
|
The Regulatory Requirements on Nitrosamines in the Pharmaceutical Industry
|
Regulatory Affairs |
19-20 |
|
|
|
|
|
11-12 |
|
|
|
|
|
|
Thinking Beyond Traditional GMP
|
GxP |
|
|
|
|
|
15-16 |
|
|
|
|
|
|
|
US FDA - Understanding Key Factors When Working with the FDA
|
Biopharma |
|
|
|
7 |
|
|
|
|
|
|
|
|
|
Understanding Pharmacovigilance Regulations in China
New for 2027
|
Vigilance |
27 |
|
|
|
|
|
11 |
|
|
|
|
|
|
Understanding Scientific Journal Submission and Publication
New for 2026
|
Medical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
|
Upstream and Downstream Manufacturing in the Biopharmaceutical Industry
New for 2026
|
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
|
Variations to Marketing Authorisations
|
Regulatory Affairs |
|
|
14-15 |
|
|
|
|
10-11 |
|
|
|
|
|
Writing Inspection-Ready SOPs: Best Practice for Compliance and Control
|
Regulatory Affairs |
|
6 |
|
|
|
|
|
25 |
|
|
|
|